TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06479733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: buccal pedicle flap
Description: For the first group (buccal pedicle flap group), outlining the full-thickness palatal flap 1 mm greater than the diameter of the underlying cover screw will be done, making a partial incision at the hinge portion of the created mini-pedicle flap to facilitate buccal rolling, de-epithelializing the mini-pedicle flap, then two small vertical incisions will be performed similarly mesial and distal to the screw border as wide as possible preserving the papilla and extending labially to include all the keratinized mucosa, elevating a full-thickness flap, then rolling of the pedicle flap into the created buccal pouch. The flap will be then sutured all around in place using a 5/0 vicryl suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: For the second group (free CTG group), masticatory mucosa on the palate between palatal raphae and maxillary posterior teeth is the most common location for the donor site for free CTG. It will be obtained by harvesting and de-epithelializing FGG asbeing a CTG derived from de-epithelialization of FGG mainly composed of lamina propria. Then the donor site will be covered by gel foam , sutured and protected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acellular dermal matrix
Description: * For the third group (ADM group) , The matrix will be trimmed so that it is gently adapted to the artificial envelope created on the buccal aspect of the ridge.The matrix will be trimmed and beveled to make its adaptation into the artificial envelope easier. Before placement, matrix will be hydrated for 10 minutes in fresh human blood collected after flap elevation in each patient.~* For both second and third groups, graft will be carefully positioned under the buccal pouch, sutured to it, light pressure will be applied over the inserted graft with moist gauze for 10 minutes to minimize blood clot and dead space formation between the graft and the underlying bone.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: only placement of dental implant without soft tissue augmentation
Study: NCT06145854

Intervention type: DRUG
Intervention: Cabotegravir Injection [Apretude]
Description: Apretude for PrEP
Study: NCT05042193

Intervention type: OTHER
Intervention: SARS-CoV-2
Description: Observational

Intervention type: OTHER
Intervention: SARS-CoV-2
Description: Observational
Study: NCT06031194

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04588142

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Non-elite athletes receive probiotic for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-elite athletes receive placebo for 6 weeks
Study: NCT06070376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully Covered Esophageal Prosthesis (FC-SEMS)
Description: The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially Covered Esophageal Prosthesis (PC-SEMS)
Description: The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
Study: NCT06042946

Intervention type: PROCEDURE
Intervention: Microsurgical resection of ISCM
Description: Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
Study: NCT05203432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light Intervention
Description: Repeated Low-Level Red-Light Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 0.01% atropine
Study: NCT05316844

Intervention type: OTHER
Intervention: There will be no interventions.
Description: Measurements and performance tests were conducted to investigate predictors of work-related performance
Study: NCT06467409

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patient-controlled analgesia(PCA) administration
Study: NCT05849701

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave therapy
Description: using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-assisted closure
Description: Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
Study: NCT05903170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 360J LifePak Monitor/Defibrillator
Description: The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 200J Philips HeartStart MRx Monitor/Defibrillator
Description: The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
Study: NCT06467409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine hydrochloride injection
Description: patient-controlled analgesia(PCA) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: patient-controlled analgesia(PCA) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: patient-controlled analgesia(PCA) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: patient-controlled analgesia(PCA) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3480392 Injection
Description: patient-controlled analgesia(PCA) administration
Study: NCT06131190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness training
Description: it focuses on attention and has gained empirical support as a complementary or alternative intervention
Study: NCT06179537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Single and multiple doses assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Single and multiple doses assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Single and multiple doses assessment
Study: NCT04930991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole
Description: Treatment will consist of Omeprazole 2 weeks prior to surgical therapy of pancreatectomy.
Study: NCT04838288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Change from Prograf to Envarsus XR
Description: Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
Study: NCT05244915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (Focus Groups)
Description: Focus group qualitative interviews will be conducted with key stakeholders consisting of older adults with cancer and their caregivers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Description: Qualitative interviews will be conducted with older caregivers of older adults with cancer to inquire about their experience with caregiving and unmet supportive care needs.
Study: NCT06253338

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: genomic alterations
Description: Alteration of the genome under radiotherapy
Study: NCT06322615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive education session about using acupressure at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06531642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days
Description: Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protonix (pantoprazole) 40 mg q 24 hrs for 2 days
Description: Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
Study: NCT06533371

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Relationship between lung ultrasound and computed tomographic scan
Description: Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Relationship between lung ultrasound and computed tomographic scan
Description: Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems.
Study: NCT05235425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard NDPP
Description: Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's standard National Diabetes Prevention Program. It teaches a lower calorie, lower fat diet.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Description: Participants in this arm will be taught to manage their prediabetes with the Centers for Disease Control's National Diabetes Prevention Program, adapted to teach a very low-carbohydrate diet, also called a ketogenic or keto diet. This diet involves eating non-starchy vegetables, leafy greens, cheese, meats, berries, nuts, and seeds and avoiding starchy foods like pasta, bread, rice, beans, many fruits, etc.~There will be a core phase and a maintenance phase of this study; the core phase will last for about 4 months and will involve weekly or every other week classes, home assignments, and brief check-in surveys. The maintenance phase will last for the remaining time, with classes and check-in surveys approximately once a month.
Study: NCT04802408

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Shampoo and saline
Description: Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Saline and Listerine
Description: Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Shampoo and Listerine
Description: Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Saline and Saline
Description: Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
Study: NCT04443569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
Study: NCT04565496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
Study: NCT04986150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
Study: NCT04972279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital message (text + image)
Description: Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital message (text + image)
Description: Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity).
Study: NCT06172140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol group
Description: All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol group
Description: All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
Study: NCT06424743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise programs with different volumes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise programs with different volumes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise programs with different volumes
Study: NCT06404541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, tobramycin, netilimicin
Description: Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, tobramycin, netilimicin
Description: Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, tobramycin, netilimicin
Description: Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
Study: NCT06332157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection Emulsion
Description: In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
Study: NCT05751577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI WITHOUT ON-SITE SURGERY
Description: After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVI WITH ON-SITE SURGERY
Description: After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
Study: NCT05354219

Intervention type: OTHER
Intervention: Imaging
Description: Imaging with 3 iris cameras

Intervention type: OTHER
Intervention: Imaging
Description: Imaging with 3 iris cameras
Study: NCT04951349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-03
Description: Same dosage used in Bactroban Nasal studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-03
Description: Same dosage used in Bactroban Nasal studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum ointment
Description: Viscous ointment similar in form to study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum ointment
Description: Viscous ointment similar in form to study drug.
Study: NCT06408688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitors plus Iscador® Qu.
Description: Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune Checkpoint Inhibitors
Description: Standard cancer treatment.
Study: NCT06491745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT+PT+corticosteroid injection, ESWT group
Description: ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham ESWT+PT+corticosteroid injection, SHAM group.
Description: SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.